- Home
- PSFE vs ZYME Comparison
PSFE vs ZYME Comparison
Compare PSFE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- ZYME
- Stock Information
- Founded
- PSFE 1996
- ZYME 2003
- Country
- PSFE United Kingdom
- ZYME United States
- Employees
- PSFE N/A
- ZYME N/A
- Industry
- PSFE Business Services
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- PSFE Consumer Discretionary
- ZYME Health Care
- Exchange
- PSFE Nasdaq
- ZYME Nasdaq
- Market Cap
- PSFE 1.1B
- ZYME 983.6M
- IPO Year
- PSFE N/A
- ZYME 2017
- Fundamental
- Price
- PSFE $15.78
- ZYME $11.86
- Analyst Decision
- PSFE Sell
- ZYME Buy
- Analyst Count
- PSFE 4
- ZYME 6
- Target Price
- PSFE $17.88
- ZYME $19.50
- AVG Volume (30 Days)
- PSFE 419.1K
- ZYME 728.6K
- Earning Date
- PSFE 03-04-2025
- ZYME 03-05-2025
- Dividend Yield
- PSFE N/A
- ZYME N/A
- EPS Growth
- PSFE N/A
- ZYME N/A
- EPS
- PSFE 0.36
- ZYME N/A
- Revenue
- PSFE $1,704,835,000.00
- ZYME $76,304,000.00
- Revenue This Year
- PSFE $2.71
- ZYME $19.85
- Revenue Next Year
- PSFE $5.94
- ZYME $100.06
- P/E Ratio
- PSFE $43.53
- ZYME N/A
- Revenue Growth
- PSFE 6.48
- ZYME 0.38
- 52 Week Low
- PSFE $14.06
- ZYME $7.97
- 52 Week High
- PSFE $26.25
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- PSFE 39.69
- ZYME 38.43
- Support Level
- PSFE $14.11
- ZYME $11.52
- Resistance Level
- PSFE $18.15
- ZYME $13.28
- Average True Range (ATR)
- PSFE 0.62
- ZYME 0.57
- MACD
- PSFE 0.01
- ZYME -0.01
- Stochastic Oscillator
- PSFE 22.23
- ZYME 10.26
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet, and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.